- Home
- ABTS vs EPIX Comparison
ABTS vs EPIX Comparison
Compare ABTS & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- EPIX
- Stock Information
- Founded
- ABTS 2010
- EPIX 2009
- Country
- ABTS Hong Kong
- EPIX Canada
- Employees
- ABTS N/A
- EPIX N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- ABTS Technology
- EPIX Health Care
- Exchange
- ABTS Nasdaq
- EPIX Nasdaq
- Market Cap
- ABTS 8.9M
- EPIX 9.0M
- IPO Year
- ABTS N/A
- EPIX N/A
- Fundamental
- Price
- ABTS $10.13
- EPIX $0.21
- Analyst Decision
- ABTS
- EPIX Hold
- Analyst Count
- ABTS 0
- EPIX 3
- Target Price
- ABTS N/A
- EPIX $2.00
- AVG Volume (30 Days)
- ABTS 50.6K
- EPIX 3.2M
- Earning Date
- ABTS 08-13-2025
- EPIX 08-13-2025
- Dividend Yield
- ABTS N/A
- EPIX N/A
- EPS Growth
- ABTS N/A
- EPIX N/A
- EPS
- ABTS N/A
- EPIX N/A
- Revenue
- ABTS $7,037,156.00
- EPIX N/A
- Revenue This Year
- ABTS N/A
- EPIX N/A
- Revenue Next Year
- ABTS N/A
- EPIX N/A
- P/E Ratio
- ABTS N/A
- EPIX N/A
- Revenue Growth
- ABTS 31.69
- EPIX N/A
- 52 Week Low
- ABTS $1.35
- EPIX $0.18
- 52 Week High
- ABTS $14.10
- EPIX $6.48
- Technical
- Relative Strength Index (RSI)
- ABTS 73.79
- EPIX 11.92
- Support Level
- ABTS $9.05
- EPIX $0.20
- Resistance Level
- ABTS $10.70
- EPIX $0.23
- Average True Range (ATR)
- ABTS 1.38
- EPIX 0.02
- MACD
- ABTS 0.24
- EPIX 0.06
- Stochastic Oscillator
- ABTS 87.90
- EPIX 45.85
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.